


Breadcrumb

1. [Home](#)

Entity Print



Tobias Alexander
ADWP Chair (ELECTED APRIL 2024, PREVIOUS CHAIR: Raffaella Greco)
Germany

Major achievements

For autoimmune diseases (ADs) not sufficiently responding to state-of-the-art immunosuppressive or biologic therapies, haematopoietic stem cell transplantation (HSCT) has been successfully implemented as treatment option in carefully selected patients, with endorsement as standard indication for systemic sclerosis and multiple sclerosis from international societies, such as EULAR (Del Galdo et al., *Ann*

Rheum Dis. 2024) and ECTRIMS (Muraro et al., *Nat Rev Neurol.* 2025). The EBMT Autoimmune Diseases Working Party (ADWP) has been central to development of these approaches. Currently, 4656 patients have been reported to the EBMT registry (Fig. 1).




Figure 1: Auto-HSCT cases reported to the EBMT Registry

Recent achievements from our working party include a position paper developed in collaboration the Patient Advocacy Committee (PAC) and Nurses Group of the EBMT on **patient related outcome parameters to be considered in HSCT recipients for ADs** (Alexander et al., *J Allergy Clin Immunol Glob.* 2024). Furthermore, we conducted a **survey on the centre policy on ATG usage** (Ismail et al., *Bone Marrow Transplant.* 2024) as well as **monitoring and managing viral reactivations post-transplantation for ADs** (Alexander et al., *Bone Marrow Transplant.* 2025). In cooperation with the EBMT Chronic Malignancies Working Party, we retrospectively analysed the **outcome of patients with VEXAS syndrome undergoing allogeneic HSCT** (Gurnari et al., *Blood Advances.* 2024).

Recently, innovative cellular therapies (i.e. CAR-T cells, mesenchymal cells, Tregs-based therapies) have been successfully adopted in ADs. To this end, we published an expert-based position statement and clinical practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee on **innovative cellular therapies for ADs** (Greco et al, *EClinicalMedicine.* 2024) and provided an update

on the **role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in immune-mediated neurological diseases** (Brittain et al., *Ann Neurol.* 2024).

The ADWP is dedicated to promoting clinical activities, teaching and translational research on HCT together with innovative cellular therapies as AD treatment. We continued to expand the evidence-base and support best-practice with studies and guidelines, including significant collaborative outputs with the EBMT Working Parties, JACIE, Trainee Committee, PAC and Nurses Group. Education is central in ADWP activities, including an educational meeting on “Immunology and Cellular Therapies in Autoimmune Diseases” held in Milano (Fig 2.), and a harmonisation workshop on HSCT in rheumatic diseases that took place in Lille 2024. Moreover, a section specifically designed for ADs was developed within the EBMT e-learning platform with contributions from key experts in the field.



Joint Educational Meeting of the ADWP and CTIWP - Milan, Italy - 10-12 October 2024

Principal research studies

[Comparison of Cyclophosphamide/ATG vs BEAM/ATG conditioning regimens in autologous HSCT for Multiple Sclerosis](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Auto immune disorders](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Type of treatment](#)

[Autologous](#)

[Principal investigator](#)

[Riccardo Saccardi](#)

Post AHSCT (Autologous Hematopoietic Stem Cell Transplantation) management for patients with systemic sclerosis: a prospective, non-interventional approach across Europe (NISSC-2)

Study type

Non-interventional Prospective Studies

Diseases

-

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

Autologous

Principal investigator

Pr Dominique Farge

Observational Study in Multiple Sclerosis patients treated with autologous hematopoietic stem cell Transplantation (OMST)

Study type

Non-interventional Prospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

Autologous

Principal investigator

Riccardo Saccardi

Incidence and outcome of CMV and EBV reactivations after autologous HSCT for autoimmune diseases: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type

Retrospective Studies

Diseases

Auto immune disorders

Group

Autoimmune Diseases Working Party (ADWP)

Type of treatment

-

Principal investigator

[Tobias Alexander](#)

[CAR-T Cell Therapy in Autoimmune Diseases as Concomitant or Main Indication: a 2-step Joint Study on behalf of EBMT ADWP and CTIWP](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[Auto immune disorders](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Raffaella Greco](#)

Key publications

[2024](#)

[Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Raffaella Greco](#)

[Journal](#)

[EClinicalMedicine.](#)

[2024](#)

[Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Chronic Malignancies Working Party \(CMWP\)](#)

[1st listed author](#)

[Carmelo Gurnari](#)

[Journal](#)

[Blood Adv.](#)

[2024](#)

[The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Gavin Brittain](#)

[Journal](#)

[Ann Neurol.](#)

[2024](#)

[ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party \(ADWP\)](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[1st listed author](#)

[Azza Ismail](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2024](#)

[Patient-reported outcomes in HSCT for autoimmune diseases: Considerations on behalf of the EBMT ADWP, PAC, and Nurses Group](#)

[Group](#)

[Autoimmune Diseases Working Party \(ADWP\)](#)

[Patient Advocacy Committee](#)

[Nursing Research Committee](#)

[Nursing Scientific Committee](#)

[1st listed author](#)

[Tobias Alexander](#)


[Journal](#)

[J Allergy Clin Immunol Glob.](#)

[See the full list of the ADWP 2024 publications](#)



Indicators



	2022	2023	2024
Oral presentations	22	16	8
Poster presentations	1	4	1
International educational events	3	3	2

Major educational events



[Event](#)

50th Annual Meeting of the EBMT



[Kingdom](#)

[Event](#)

9th International Transplant and Cellular Therapy Course



Event

Immunology and Cellular Therapies in Autoimmune Diseases

Oct 10, 2024 - Oct 12, 2024 / Milan, Italy

Discover more

Webinars and e-courses

HSCT in Autoimmune Diseases E-Course

Panel Discussion: Autologous HSCT in Multiple Sclerosis

VISIT THE ADWP WEBPAGE